Prescription medicine
Dexchlorpheniramine Brand names: Corphena, Ryclora
Dexchlorpheniramine (Ryclora) is a prescription medicine. A generic is approved and listed by 2 labelers, but in the October 7, 2026 NADAC survey pharmacies bought only the brand, at $2.90 per mL (Ryclora 2 mg/5 mL solution).
- Generic approved
Check it at the source: the dexchlorpheniramine FDA label on DailyMed (effective December 22, 2025, BluCrest Pharmaceuticals LLC); every dexchlorpheniramine label on DailyMed.
Highlights of the record
FDA label of December 22, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usagePerennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
Forms and strengths
- 2 mg/5ml
Solution; liquid.
On the market
- Generic approvals
- 5 first July 14, 1981; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 2 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.90 per mL Ryclora 2 mg/5 mL solution
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 990 through July 30, 2026
What is dexchlorpheniramine used for?
From the label: indications and usagePerennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
Source: FDA drug label (Corphena), ANDA202520 (Pharmobedient), as published by BluCrest Pharmaceuticals LLC, effective December 22, 2025 (SPL set 4694616b-4ef4-28a4-e063-6394a90ac5f6), via openFDA; the full label on DailyMed
Is there a generic for dexchlorpheniramine (Ryclora)?
The FDA approved the first generic dexchlorpheniramine on July 14, 1981. 5 generic applications are approved; 1 of them carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists dexchlorpheniramine from 2 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it. In the latest NADAC survey pharmacies bought only the brand, so a generic may not be on sale yet.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for dexchlorpheniramine (Ryclora)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.90 per mL (Ryclora 2 mg/5 mL solution), up 2% from $2.85 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ryclora 2 mg/5 mL solution (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ryclora 2 mg/5 mL solution | Brand | $2.90 per mL | n/a | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for dexchlorpheniramine?
The FDA Adverse Event Reporting System holds 990 reports that list dexchlorpheniramine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 144 are coded as a death and 565 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Dexchlorpheniramine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other